Wolfe Research initiated coverage of Pharvaris (PHVS) with an Outperform rating and $42 price target The firm is bullish on the company’s prophylactic data expected in Q3 and expects it to be the biggest stock mover of 2026. Pharvaris’ deucrictibant will “own” the oral subset of the hereditary angioedema market with “Takhzyro-like efficacy,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris price target raised to $42 from $41 at Wedbush
- Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
- Pharvaris price target lowered to $51 from $52 at RBC Capital
- Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
- Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year